The Universities of Edinburgh and Glasgow join forces to train young doctors in musculoskeletal disease

The Universities of Edinburgh and Glasgow are joining forces to train young doctors in research relevant to the causes and treatment of musculoskeletal disorders. The ambitious new project which will see the institutions combine their global excellence in biomedical research and teaching to advance understanding of musculoskeletal diseases.

The new TRAM (Train and Retain Academic Musculoskeletal Clinicians) programme is supported with a £2m grant from The Kennedy Trust for Rheumatology Research, and will offer opportunities for medical students interested in areas relevant to rheumatology and musculoskeletal disease to undertake a PhD doctorate alongside their medical training.

TRAM is the third joint PhD medical programme shared between the two Scottish institutions, after the MRC Doctoral Training programme in Precision Medicine and the Cancer Research UK TRACC (Train and Retain Academic Cancer Clinicians) programme, which successfully recruited its first cohort of students during 2020. TRAM will be integrated within TRACC in order to build on this existing success, and to further strengthen the research and teaching collaboration between the two institutions.

Rheumatology research is a key focus for both the Universities of Edinburgh and Glasgow. The University of Edinburgh, hosts an internationally renowned programmes of research into musculoskeletal disease at the Centre for Genomic and Experimental Medicine, and at the Centre for Inflammation Research (CIR). The CIR, alongside the MRC Centre for Regenerative Medicine, are major components of its new £55M Institute of Repair and Regeneration at Edinburgh which will open in 2022. At the University of Glasgow, the Institute of Infection, Immunity and Inflammation leads the Versus Arthritis Rheumatoid Arthritis Centre of Excellence and is the coordinating centre for the MRC-funded IMID-BIO.

This award reflects the world-leading clinical and teaching expertise that we are so fortunate to have across the Universities of Edinburgh and Glasgow. It has been estimated that one-third of all consultations in general practice are for musculoskeletal disease. I am confident that this innovative programme will support a new generation of clinician-scientists to improve outcomes for people living with musculoskeletal diseases over the coming years.